GLP-1s and Vision Loss - How Worried Should You Be? w/ Dr. Luke Sorrell

If you're taking a GLP-1, headlines about sudden vision loss can leave you wondering whether the medication helping you lose weight is putting your eyesight at risk. Ana Reisdorf talks with Dr. Luke Sorrell about NAION, a rare optic nerve condition, and the semaglutide research behind those headlines. You'll learn how to put "double the risk" into perspective, what questions to bring to your doctor, and why your health history matters to the conversation.

**IN THIS EPISODE**

- What NAION is and how it can affect vision
- What semaglutide studies suggest, and the limits of observational research
- Why relative risk and absolute risk tell different parts of the story
- How diabetes, sleep apnea, cardiovascular health, and optic nerve anatomy fit into the discussion
- Blood pressure changes, dehydration, and rapid blood sugar changes as possible contributing factors
- Questions to ask your prescriber and eye care professional about your individual risk
- What remains uncertain about tirzepatide and other GLP-1 medications
- Weighing potential eye risks alongside the benefits of GLP-1 treatment

**ABOUT THE GUEST**

Dr. Luke Sorrell is a board-certified internal medicine physician, Fellow of the American College of Physicians, and founder of Sorrell MD, a concierge longevity and precision telemedicine practice based in Dallas-Fort Worth, Texas, serving patients across the U.S. He trained at UT Houston McGovern Medical School and completed his residency at Baylor University Medical Center in Dallas. His career has spanned hospital medicine, primary care, and longevity medicine. Today, he works with high-performing and health-conscious individuals across the country, using tools like cardiac CT angiography, VO2 max and metabolic testing, DEXA, genomics, and advanced hormone and lipid panels to identify health risks earlier. He also advises health tech companies building the next generation of care.

**CONNECT WITH DR. LUKE SORRELL**

Website: https://www.sorrell-md.com
LinkedIn: https://www.linkedin.com/in/luke-sorrell-md/
Instagram: https://www.instagram.com/sorrellmd/
Facebook: https://www.facebook.com/SorrellMD
Substack: https://substack.com/@sorrellmd

**SPONSOR**

Tyde Wellness offers GLP-1 care with licensed providers, nutrition guidance, and ongoing support. Use code GLP1Hub50 for $50 off your first month.
https://tydewellness.com/GLP1Hub

**CHAPTERS**

00:00 GLP-1s and NAION: The "double risk" headline
01:42 Meet Dr. Luke Sorrell
02:52 What is NAION?
05:10 How rare is NAION?
06:13 Diabetes, sleep apnea, and other risk factors
07:50 What the studies show and their limitations
10:49 Relative risk versus absolute risk
11:58 Sponsor: Tyde Wellness
13:22 Semaglutide, tirzepatide, and unanswered questions
14:22 Possible mechanisms: Blood pressure, oxygen, and hydration
19:05 Eye exams, optic nerve anatomy, and rapid A1C changes
22:15 Questions to bring to your doctor
24:54 Ana's Plateau Breakthrough Playbook
26:15 Staying grounded when health headlines spread
27:20 Retatrutide and the future of GLP-1 treatment
29:31 Connect with Dr. Sorrell
30:01 Weighing eye concerns against cardiovascular benefits
31:25 Closing thoughts and podcast reviews

MORE FROM GLP-1 HUB

📬 Get The Steady State, Ana's weekly newsletter with GLP-1 guidance from a dietitian who's on one: http://join.glp-1hub.com

🎙 Subscribe wherever you listen to podcasts, and if this episode helped, leave a quick review on Apple Podcasts or Spotify - it's the single best way to help more people find the show.

🌐 Shop GLP-1 essentials, meal plans, and recipes: https://shop.glp-1hub.com
📷 Follow on Instagram: @glp1hub
📺 Watch on YouTube: https://www.youtube.com/@GLP-1hub

*Some of the links shared are affiliate links. When you make a purchase, I will receive a small commission at no cost to you. Thank you for supporting the show.

*The content of this show is for informational purposes only and does not constitute medical advice. The goal of this show is to provide various points of view about GLP-1 Medications. The personal and professional opinion of the guests and their content does not necessarily reflect the opinion of Ana Reisdorf or GLP-1 Hub.

Transcript

Copy Transcript Copied

SPEAKER_00 0:00

So between 2024 and now, there's been more data. Nothing's been conclusive, but pooling all of the data that we've got probably lands somewhere around two times the risk for people who are using GLP1s and are diabetic. They're at maybe twice the risk of nion.

SPEAKER_01 0:20

If you've seen the headlines linking GLP1 medications to sudden vision loss, you might be wondering what that really means. As a GLP1 user myself, I wanted to understand the research behind those headlines and the questions we should be asking. Welcome to the GLP1Hub Podcast. I'm Anna Reisdorf, a registered dietitian and GLP1 user. And today I'm having an important conversation with Dr. Luke Sorel, a board-certified internal medicine physician, and we're talking about nylon, N-A-I-O-N, a rare eye condition, and what the research on GLP1 tells us and what it doesn't. We'll unpack why the double risk thing you may have heard needs context, how diabetes, sleep apnea, and blood pressure fit into the discussion, and what questions you should bring to your doctor. If these headlines have left you super anxious, this conversation will help you put the numbers into perspective and have a more informed discussion about your own risks and benefits for GLP1. Now let's get into the episode. Welcome to the GLP1 Hub Podcast. So we are covering something that several of you have asked me about lately, which is sudden blindness. It seems like it's been in the media a lot. So I am going to welcome Dr. Sorel today, and he's going to tell us all the things so we are not scared. So we have the facts and we know exactly what to do. Can you introduce yourself to the people, Dr. Sorel, please?

SPEAKER_00 1:42

Yeah, you bet. Thanks so much for having me on. Uh my name's Luke. I currently live in the Dallas-Fort Worth area and have a telemedicine longevity and precision practice. So I reach people across most of the U.S., licensed most places. But yeah, I utilize GLP1s on a daily basis. And this question has been coming up recently. So excited to explore a little bit about it and distill some of the fears.

SPEAKER_01 2:11

Yeah. So I feel like a while ago people were talking about it, then it kind of went away. And then longevity researcher David Sinclair went on the Joe Rogan podcast and said that the cases of blindness have doubled. And of course, they clipped out the little tiny clip where he said those exact words. And it flew around social media. And I listened to it because I was like, oh God, am I missing something? I'm a Jill P1 user too. And there's a lot more context to what he actually said. So that's why I wanted to bring you on. So maybe we could talk through some of that. So starting like at the very beginning, what is this condition that we're talking about? The sudden blindness.

SPEAKER_00 2:52

Yep, definitely. Let's get some basic definitions and kind of some anatomy. So basically basically it stands for this acronym NION, non-arteritic anterior ischemic optic neuropathy. It's kind of a mouthful, but essentially what that is saying is it's a stroke in one eye. So classically, someone wakes up and they can't see out of their eye. That's typically how it presents. And so it's it's it's non-arteritic in the sense that it's it's not a primary disease of the artery. So some things are primary artery disease. It causes inflammation and it's it it triggers vision loss. This isn't necessarily related to the artery itself. It's more related to the fact that there was a lack of blood flow or lack of oxygenation coming into the eye, and that triggered this event. So that's what nion stands for. But you can just basically think of it as a stroke in one eye.

SPEAKER_01 3:48

Okay. And so it's not connected to having like a stroke in your brain at all.

SPEAKER_00 3:53

Not necessarily, although it's similar. It's similar to that. A stroke in your brain, again, is is related to lack of blood flow. So something cuts the blood flow off, or or you you had a drop in the pressure and you can push the blood up into the brain, and that's what triggers a stroke. So it's similar in that sense, but it's happening in the eye. And so the risk factors for it can be interchangeable. Risk factors for a stroke and and nion, we can talk about, are similar. So it's similar in that blood flow sense.

SPEAKER_01 4:25

Okay. So you just wake up and one eye is just gone.

SPEAKER_00 4:28

Typically, yeah. And it can be varying degrees of vision loss. It may be full, it may just be partial.

SPEAKER_01 4:33

Okay.

SPEAKER_00 4:34

So it can vary. Yeah.

SPEAKER_01 4:35

That's a little bit better.

unknown 4:37

Correct. Yeah.

SPEAKER_00 4:39

And it can, and it can, you know, over it, it's something that, you know, some people can regain some of their vision over time. Some people it it it never recovers. So there's varying degrees here. Um, but there's not really treatment here for it necessarily. It it's one of those things that what's it's it's happened, um, it it kind of is what it is. And and some people recover some, some people don't. And so I think understanding what it is and what causes it and how you can prevent it are are what's important here.

SPEAKER_01 5:10

Sure. So is this something that just started happening because of GLP1s, or has this been around? Has this been happening to people? We just it hasn't been in our Yeah, no, good question.

SPEAKER_00 5:21

Um, it's not new because of GLP1s. This is a known condition that's been around. Most of the data, it's rare. It doesn't happen, you know, to many people. Most of the data has the number at about 10 in 10,000 people every year on the higher end. So group of 10,000 people, one up to 10 or 2 to 10 per 100,000 people. Sorry, two to two to ten per 100,000 people per year have this. So that boils down to like maybe one in 10,000 per year. One in 10,000 per year at background might have this. So pretty rare. Exactly, pretty rare. 90, you know, nine percent, you know. And this is old, old people who are 50 plus typically older adults. Okay, one in 10,000 is kind of the background rate.

SPEAKER_01 6:13

And so what are the risk factors that cause this to happen? Like what I've heard it connected with diabetes.

SPEAKER_00 6:19

Exactly. So the the diabetes is a big one, and that's kind of what most of the studies related to the GOP1s were related to. But nine itself, the risk factors are typically cardiovascular disease, high blood pressure, high cholesterol, sleep apnea, diabetes. Those are the big ones. Also, what that have been noted are people who use PDE5 inhibitors like syldenophyll, tadalophil, cialis, Viagra.

SPEAKER_02 6:48

Okay.

SPEAKER_00 6:49

Probably because they can drop blood pressure a little bit, which that in and of itself can be a risk factor. People who have a dip in their blood pressure at nighttime, so nocturnal hypotension. So if you if you're someone who you know your blood pressure drops low at night, or you wake up lightheaded or dizzy sometimes, that can be a risk factor as well. Other risk factors, so just people who have known eye conditions. So cataracts, previous eye to eye surgeries, eye known eye diseases that they already have might raise the risk from their baseline. But those are the main risk factors.

SPEAKER_01 7:26

Right. So you mentioned a lot of things like blood pressure, sleep apnea, cardiovascular disease, diabetes. These are all indications for use of GLP1 medications. So I was under the impression that people with these factors are just more likely to use the GLP1 medication, and therefore they are also at greater risk of this thing. So it's like kind of all connected. Is that not accurate? Like what is the data saying there?

SPEAKER_00 7:53

Right, right. No, that's a good question. And and so there could be some confounding there, of course, because these are the people who are going to be using the GLP1s. But what the what the data, what most of the data is showing, so we can kind of go through some of the data here to kind of clarify some of that. So it the the main study came out in 2024. There was a paper in Jam ophthalmology that showed that there was somewhere between four to seven times increased risk of nion in GLP1 users. But this was a small study.

SPEAKER_01 8:25

And that was regardless of their diabetes or their blood pressure or all of that.

SPEAKER_00 8:30

It didn't necessarily stratify everything out. So it was GLP1 users. Diabetics, I think, were four times more likely. People who were just obese and using it were seven times more likely in this study.

SPEAKER_02 8:42

Okay.

SPEAKER_00 8:43

But again, it was a small study, so it you couldn't draw big conclusions. And it was a study single center focused on a neuro ophthalmology referral center. So basically the place where all the these people who have these weird eye conditions like nion are gonna get referred to. So there's gonna be some selection bias here. So this is the place where all these nion patients are gonna get referred to. And so uh that's gonna inflate everything because of that selection bias. So small study, selection bias. But again, it put it on the radar. It looks like there could be an increased risk, somewhere four to seven times the baseline. So between 2024 and now, there's been more data. Nothing's been conclusive, but big the pooling all of the data that we've got probably lands somewhere around two times the risk for people who are using GOP1s and are diabetic, they're at maybe twice the risk of nion. If they have cardiovascular issues, so there were some VA studies. People, you know, if you're familiar with the VA, tend to have more cardiovascular problems. You know, they've got all the things, sleep apnea, cardiovascular disease, blood pressure, cholesterol, all of it. Their risk in those studies was 10, about 10 times, right? None of these studies are going to prove anything. It's observational, it's not hard data that you can really draw conclusions from, but with all those risk factors, it was maybe about 10x. Some studies didn't show any association. So we've got varying, varying uh levels of data here. This past May, the American Academy of Ophthalmology put out a consensus on all this. They went through all of the data, all the studies, 40 plus studies. Their conclusion was that people on semaglutide, because most of these studies were semaglutide, semaglutide and diabetes risk was probably about 2x. That was the best recommendation, you know, best observation from all of the studies they could make.

SPEAKER_01 10:47

So is that where David Sinclair got his double number?

SPEAKER_00 10:50

That's where he got his double number. But this is yeah, this is this is where that doubling or that 2x number could be misleading to people because it's a relative number, it's a relative risk number. So double or twice the risk of a of a low risk condition is still low. Right? So the risk of this, just background normal person out there, one in 10,000 at the high end, one in 10,000 per year. So double, we're at two in 10,000, right? So that's still a 99.98% chance that you're not gonna have so you have to put you have to put the numbers in perspective. You can't just go out there and say two times the risk of of this. It's accurate, but but sometimes you need to to know what the absolute risk numbers are. One in ten thousand, now we're at two in ten thousand, and still very, very low. Yes, it's doubled, but when you double a small number, it's still small.

SPEAKER_01 11:52

Right, right. No, that totally makes sense. You guys remember my conversation with Beth a while back, the one that became one of the most popular episodes? Well, Beth is from Tide Wellness, and that conversation is the reason I'm comfortable telling you about them today. So many people lose weight on GLP1, feel amazing, and then six months later, they're back to where they started because the program ended or the provider disappeared, or they were never set up for the long haul. But Tide Wellness is built differently. Licensed providers who actually adjust your dosing as your body changes, a real care team you can message when you hit a plateau or have a question or need help. Nutrition guidance designed specifically for how GLP1s change your appetite. And if you've got questions, you can book a consultation and actually talk to a provider, a rare find in this space. If you're looking for more than GLP1s, they also do microdose GLP1 programs, hormone therapy, longevity peptides, and the kind of support that matters when you're trying to feel your best long term. Tide is built with support by a team that really cares. Go to tidewellness.com backslash GLP1 hub and use the code GLP1Hub50 for $50 off your first month. Again, that's Tide T Y D E wellness.com backslash GLP, the number one hub, and the code is GLP1. So a few questions. You mentioned that most of the research has been done on semaglutide. So I had a couple people ask me if this would possibly apply to trazepatide and if it would apply to the oral medications, which still the Wagovi is still semaglutide. So would that be is do we know or are we guessing?

SPEAKER_00 13:42

Yeah, I think we don't know because most of the data is semaglutide. One. We'll have, you know, semaglutide came out first, of course, or it was there were a couple before that, but it was the it's the main one that people are using now. We have the most data on. We'll have more data on terzepatide probably in a couple of years. But it's probably applies as a class. I don't think it's anything that's specific to semaglutide itself. I think it's more of a class effect and and and and and is more of an effect of what these or a consequence of what these drugs are doing. And so we can, if you want, we can maybe talk about like maybe what some what what the cause is.

SPEAKER_02 14:21

Yeah.

SPEAKER_00 14:22

We don't necessarily know, but we can hypothesize and theorize a little bit about okay, what is it about this drug, semaglutide, or probably just the class GOP1s as a whole that's causing nion? What is it doing?

SPEAKER_01 14:36

Yeah.

SPEAKER_00 14:37

So I think if we think back to what the risk factors are for nion first, so we've got cardiovascular disease, blood pressure, cholesterol, you know, heart attack, stroke, that history, sleep apnea, the nocturnal dip in blood pressure. These are all kind of the key things that we've we've noted are risk factors. And then use of the erectile dysfunction drugs, C L S VI, they also can dip blood pressure sometimes. I think that's important. So if you think about that in context, what is all of that potentially doing to blood flow into the eye vessel? It's potentially restricting blood flow. So if you have cardiovascular disease, you know, you've got plaque in your arteries, your heart, everywhere, even the little tiny arteries feeding your optic nerve. Yeah. And that's restricting blood flow. So if you're if you're having nocturnal drops in blood pressure, that dip in blood pressure, well, now it's going to make it harder to perfuse those little little arteries in the eye. So think about it from a blood flow and restriction of blood flow or a dip in blood flow as what's potentially triggering this in some people. The other thing, the one other thing that they've noted with nion that's a risk factor is the actual eye itself. So if you the the optic nerve is the main nerve that feeds into the eye, and that's the nerve that's affected here with nion. And it feeds through this little tunnel called the optic disc. And in some people, that tunnel is tight. So it's compressing a little bit on that nerve as it's running through it. So think of it as like a hose that's that's going through a tight space and it's getting clamped off a little bit. So the pressure on the other side is starting to weaken. You're not getting that fast flow. And so if anything cuts that off even further, if the the you you shut the valve a little bit, so the pressure's less, you lose flow at the other end. If something compresses that down further, you lose flow at the other end. That's the context to think about this condition in. Um, and I think that's the setup for where we're seeing this play out here. So now think back to the GLP ones. How could that be playing a role here? So if you're on a GLP1 and you have high blood pressure and you lose a lot of weight, what happens?

SPEAKER_01 16:52

A lot of times it goes should go down.

SPEAKER_00 16:54

Should go down, hopefully. And you can maybe come off of your medication. But if you're not paying attention, you can just stay on your full, you know, three or four blood pressure medicines. All of a sudden, I'm getting dizzy. I'm standing up and I'm like almost passing out because my blood pressure is now super low. And at nighttime now it's dipping even further. So now think of that pressure gradient. We're we're turning the valve off, or we're not pushing as much through that tight space and not perfusing the eye, and that's what can set up this happening. So blood pressure dips important, uh, or sleep apnea. So at night, if you've got sleep apnea, what happens? You stop breathing. You have these apnea episodes where you're not breathing, and so your oxygen levels go down. Well, if our arteries perfusing our eye are already limited in how much blood flow is getting through there, and now there's not enough, not as much oxygen in there, that could trigger this. Or just someone who has that nocturnal dip in blood pressure and they're they're on a GLP one. Now it's going to dip even further. Or this happens a lot, and you probably see this on the on the nutrition side. People start GLP ones and then they their nutrition kind of declines. They're not eating enough, they're not drinking enough. And sometimes they get dehydrated, even sometimes they get admitted to the hospital because they're so dehydrated. And so if that happens, that lowers your blood pressure, that causes a dip in that perfusion pressure.

SPEAKER_01 18:26

You've given me some new ways to get them to eat better now. Be like, hey, drink your water, eat your protein, eat your calories, or you're gonna be black. Muscle health wasn't working.

SPEAKER_00 18:38

Yeah, yeah, you can use this one out. So so yeah, I I think that these are all the potential things here. I don't I don't know if it's the actual drug itself is doing something weird to the eye. I think it's more of the off effects that we're getting in people at risk already. So someone who's already got a tight little optic disc, and you can go to your ophthalmologist or your optometrist and they can tell you if you've got a tight optic disc.

SPEAKER_01 19:05

If you're my nurse practitioner is telling me that that knowing that is very expensive. Like I don't I hadn't heard that before to test the size of your optic disc.

SPEAKER_00 19:15

I haven't heard that. I thought that that was a relatively straightforward thing when they're when they're doing an eye exam, they look back there, and they can kind of tell if it's if you've got a small cup to disc ratio is what it's called. And the number I believe is 0.2. If it's less than 0.2, it's more tight. I don't know. I'm I'm not a you know, ophthalmologist or optometrist, but uh I think that it's a straightforward thing that you can at least gauge, or you could say, hey, does it look tight? You know, and no, it looks fine. Okay, then you're not as high of a risk now. And the people who have all these risks, does that mean anyone who's on a GLP1 should go get their eyes checked? Probably not necessarily. If you're really worried about it, you can, but if you have all these risk factors, you're probably already going to your ophthalmologist regularly because you've got risk factors for eye disease. If you're a diabetic, you should be seeing your ophthalmologist regularly. So you should have some sense or be able to check on that. So yeah, I think these are all the the other the one other thing to mention in terms of how does it trigger this is the in diabetics, diabetic specifically. So I think in general, a common a good rule of thumb, uh just in in general, is that quick, rapid change is usually not a good thing, even if it's for the better. It slow, gradual change is usually best. Even uh so even rapid change in the positive direction, usually not good. And I think that applies to GLP1s in terms of weight. But also, if you're a diabetic and you rapidly correct your blood sugars in A1C, yes, it's great, but sometimes that can trigger some compensatory responses that aren't great. So it we know that rapid A1C reduction can actually cause or worsen uh diabetic retinopathy. Um, and and in this case with nion, it may be also a trigger. Rapid A1C change can cause some weird compensatory swelling and microvascular issues in these arteries, and that can pose an issue for restricting blood flow. So, you know, just like we like to see people gradually lose weight, um, I think gradual A1C reduction is also important because that could potentially be a risk here.

SPEAKER_01 21:25

Yeah, I think that we get excited and then forget that like the body's whole goal is is stability, right? Like it does all this stuff to make your pH not go too crazy and to keep everything like stable and it doesn't like change.

SPEAKER_00 21:40

Right. Right, right. Well, and it's gotten used, you know, our bodies have kind of they get used to this new set point and they're trying to compensate. So all these, you know, n nothing is nothing in in our biology happens in isolation. It's also connected to to to to every so many different systems, and so so many different compensatory reactions happen. To try to keep your body in a in a you know stable place. And so then when we rapidly correct something, well, that could throw something else off. And so yeah, I think it's it's a general principle principle that that kind of applies to a lot of things in medicine and biology.

SPEAKER_01 22:15

So if you are very if you're concerned about this, or like me, I've been on GLP1 for four years, you know, is there something I should ask my doctor or my provider for us to look at? Should I have a conversation about it? Like what are some questions that I could ask for, you know, to make sure that I don't wake up blind one?

SPEAKER_00 22:35

Definitely. No, I think definitely you should have a conversation with your provider. Um, but I think some practical things that you could think or discuss. You know, if you see your eye doctor, you could have that checked. You know, what does my cup to disc ratio look like? Is my optic nerve squeezed a little bit? If so, that's a potential risk factor. Two, if you are on blood pressure medicine, track your blood pressure regularly. Uh, work with your doctor on weaning your blood pressure medicine down as you lose weight so that you don't have dips and and drops in blood pressure that could pose a risk for this. If you know you're somebody whose blood pressure drops at night, sometimes it's hard to know. But if you wake up at night and you know, and you get dizzy standing up or wake up in the morning and your blood pressure's on, you know, really low, then if you take blood pressure medicine, you know, don't take it before bed. Take them in the morning. You can work with your doctor on maybe shifting the timing around and make sure that you're hydrating, you know, drinking enough fluids, getting enough electrolytes, salt, those sort of things before bed. And that could maybe help your blood pressure a little bit. Practical thing there. If you're if you have sleep apnea, make sure that it's treated. You know, GOP1s are a you know, can be a big help to people with sleep apnea. They can, you know, get people off of CPAPs or it's an indication for for getting on these these drugs. But uh it's also a potential risk factor for this. And so if you're treating it, think about treating it if you're not. And if you are, you know, just make sure that your settings and everything are dialed in and it's your CPAP, or if you're using an oral appliance, you know, it's all working because those are risk factors. If you're somebody who uses syldenophil or tadalophil, Viagra or Cialis, think about maybe not using it as much or use it during the day, you know, not in the evening, right before bed. Uh just trying to avoid these drops and that in blood pressure that it might cause. All these just practical things to think of, talk to your doctor about. But I think at the end of the day, none of this should necessarily be a reason. All these risk factors shouldn't necessarily be a reason to stop your GLP1 just because you're scared about them.

SPEAKER_01 24:50

Right. If you're on a GLP1 and the scale just stopped moving, this is where a lot of people panic. They cut calories lower, they eat less and less, and they double down on restriction. And honestly, it backfires. Your energy is gonna drop, your muscle drops, and your metabolism adapts, and weight loss gets even harder. This is exactly why I created my plateau breakthrough playbook, because breaking a plateau is not about eating less, it's about eating smarter. Inside the guide, I walk you through what's actually going on with your body, whether it's a metabolic adaptation, undereating protein, low movement, stress, or even digestion slowing down your progress on GLP1. Most importantly, I tell you exactly what to do instead. I show you how to adjust your nutrition without tanking your metabolism, how to support muscle so your body actually lets go of fat, and how to get things moving again without going to extremes. The bottom line is you just need a better strategy. Visit shop.glp-1 hub.com to grab the playbook and also check out all the resources that I have created just for you. You can also find the link in the show notes below. And then what I was gonna ask you is what do we do when somebody else goes on the Joe Rogan podcast or the whatever podcast and says something and it gets clipped and the media pick it up and all, you know, all the things spin out. Like, how do you stay grounded? Or how do what about us that don't maybe know and just see?

SPEAKER_00 26:33

Yes. No, it's hard. You know, you see all those clips, it can be hard. Uh, but I think for one, you know, talk to your talk to your doctor always. I think that's the most important thing. And find find a good community that you can ask questions, such as the one we're in right here. Um, I think it's a good community that you can reach out, you know, and ask these sorts of questions and and get some good feedback. But I think, yeah, I think you want to start with your with your doctor and find a you know a good community that that you can kind of to talk through and and and ask some of these questions and get some more grounded, in-depth answers and not just the the quick clip that that generates fear.

SPEAKER_01 27:13

Yeah. Don't ask in random Facebook groups too. That would be my other piece of it.

SPEAKER_00 27:17

Yeah. Right, right, right. Good.

SPEAKER_01 27:20

Nobody over there knows what they're talking about either. So one final question I like to ask. We're coming up on a on a new year soon. I feel like we just got into Q4. And 2027 is gonna be up upon us. Is there anything you ex you're excited about in in 2027 for GLP1 space?

SPEAKER_00 27:35

Yeah, I mean, you know, as you and your listeners probably know, um, there's just a big uh trial came out this past week on Redatru Tide. So this is sort of the new class of GLP1 triple agonist. Data looked really great on it. People lost a lot of weight. And so, yeah, it's gonna be, you know, it's gonna be approved at some point, maybe in 2027. So it's gonna be another option for people to lose weight and and hopefully do so, you know, with I think the hope with with Reditrutide and some of these newer agents is that you'll be able to target more of the weight loss as fat loss, not as much muscle loss because they're more potent, more fat burning. Um, and so I think that'll be exciting to kind of see their effects there. But but yeah, more more agents, you know, even in the pipeline that we're gonna be learning and hearing more about. So the GLP1 space is really exciting and lots and lots of new drugs in the pipeline.

SPEAKER_01 28:31

So yeah, it's cool, it's wild. I think this every day it's something, something new. I know everybody's been anticipating Reditrutide for a while now, and and but there seems to be even more that are equally powerful. I hope it just means that the price will go down due to more competition.

SPEAKER_00 28:46

We will see. Yeah, we will see. Hopefully that's the case. Yeah, I know with Reditru Tide, they're trying to get it classified as as a biologic.

SPEAKER_02 28:55

Yes, I heard that.

SPEAKER_00 28:56

So that they kind of compat some of the compounding. So we'll see what happens there. But that could make the price go up on that. So we'll see. Um, but yeah, it's definitely an interesting space. And I think, you know, just in general, the the advancements in the space are just rapidly progressing. And so there's gonna be a lot for people who are who are using these and who want to get on one or scared. I mean, just more, more drugs, more data, more um, more evidence is coming, you know, at rapid pace. So it's a good time to be, you know, have access to these drugs.

SPEAKER_01 29:31

Absolutely, absolutely. So, where can people connect with you if they want to learn more about your practice and the work you do?

SPEAKER_00 29:35

Yeah, you bet. I think the easiest place is is online, my website. So www.sorrel-md.com. You can uh read about me and my practice. And um, you know, if you'd like to reach out or communicate or book a call, you can do so on there. But that's the easiest place to find me.

SPEAKER_01 29:52

Awesome. Thank you so much for this. This was very calming and not panic inducing and not like a short clip of double, it's gone double, it's double now.

SPEAKER_00 30:01

Yeah, yeah. Yeah, you got you've got to look at the absolute risk, you know, the absolute risk is still small. And and I think, you know, the other thing, the last thing I would just mention that I don't think I I I I covered was, you know, the the you've got to also frame it too, and the risk of the risk, say you're someone who has all the risk factors, the risk of this is maybe at 10 per 10,000 people a year. Yeah. Your risk, though, of not being on a GLP one and experiencing a cardiovascular event. There was just a big trial, the select trial, that semaglutide reduces cardiovascular events, your risk of a cardiovascular event is is you know 150 per 10,000. If you're on a drug, you're gonna lower your risk by, you know, 150 fewer cases per 10,000. So you're you're you know, for a high-risk person, I I think the benefit of of staying on this, um, you know, and preventing a heart attack, a stroke, uh, cardiovascular death is still so much higher than just your absolute risk of of this condition. That's what you want to keep in mind. That's what you want to frame.

SPEAKER_01 31:06

Right. I think that you just gotta always like look at the risk versus versus benefits. I mean, there's there's risks of medication, but like people really need it and and it does improve their health. And so you just gotta make that out. So yeah. Thank you so much, Dr. Stoff, and I really appreciate your message and and thank you for being here.

SPEAKER_00 31:23

Yeah, thank you for having me. It was really fun.

SPEAKER_01 31:25

Thank you for listening to this week's episode of the GLP One Hub Podcast. Ever since I heard that oh, the risk is double or the rates are doubling on the uh Joe Rogan show. I I thought that was seemed kind of weird. So I wanted to like explore a little bit more what the truth was, and I thank Dr. Sarrell for coming on to talk about it. If you're enjoying this podcast, I really need some reviews, especially over on Spotify. And you don't even need to write anything on Spotify. You do have to listen to the podcast, and then you can just click on about and then click the five star reviews. It really, really helps. If you want to leave a review on Apple Podcasts where you can leave a comment, I would be grateful for that as well. Reviews help the podcast grow and help other people find it so they can be helped by this information as well. And I look forward to seeing you in the next episode.